Nettacin (Netilmicin Sulfate)

Netilmicin sulfate, the active ingredient in Nettacin, is an aminoglycoside antibiotic presented as an ophthalmic solution for ocular use. It treats bacterial conjunctivitis and other bacterial eye infections in patients requiring topical therapy.

GNH USA supplies Nettacin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nettacin is an ophthalmic antibiotic indicated for bacterial infections of the eye.

- Bacterial conjunctivitis: reduces bacterial load and promotes resolution of infection. - Bacterial keratitis: eradicates causative organisms and aids corneal healing. - Other bacterial eye infections: effective against bacterial blepharitis and ocular surface infections.

Adverse reactions are generally localized to the eye and may vary in frequency.

Common Side Effects: - Burning or stinging sensation upon instillation. - Transient eye redness. - Mild tearing or increased lacrimation. - Temporary blurred vision. - Localized itching or irritation. - Mild conjunctival hyperemia.

Serious or Rare Side Effects: - Severe ocular inflammation or allergic reaction. - Corneal ulceration or epithelial defect. - Systemic absorption leading to nephrotoxicity. - Ototoxicity in rare systemic exposure. - Vision loss if severe infection progresses. - Anaphylactic reaction (extremely rare).

When prescribing Nettacin, consider the following safety measures.

- Hypersensitivity assessment: confirm no known allergy to aminoglycosides. - Infection type verification: avoid use in viral or fungal conjunctivitis. - Renal function monitoring: use with caution in patients with impaired renal clearance. - Contact lens use: advise removal of lenses before and after administration. - Duration of therapy: limit prolonged use to reduce risk of systemic absorption. - Store at room temperature: keep in original container, protect from light and moisture.

Nettacin may interact with other medications; awareness of interaction severity is essential.

Major Interactions (Avoid): - Concurrent systemic aminoglycosides: increased risk of nephrotoxicity. - Nephrotoxic agents (e.g., vancomycin, amphotericin B): additive renal toxicity. - Loop diuretics (e.g., furosemide): heightened risk of renal impairment.

Moderate Interactions (Monitor Closely): - Topical anesthetics: may enhance corneal toxicity. - Other ophthalmic antibiotics: potential antagonistic effects. - Systemic aminoglycosides: monitor cumulative exposure.